Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Nine justices in the US Supreme Court voted unanimously to uphold lower district and federal court rulings that invalidated the patents awarded to Amgen for Repatha (evolocumab), which the company ...

As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.